Your browser doesn't support javascript.
loading
Progress in the study of new cancer target Cdk5 and its inhibitors / 药学学报
Acta Pharmaceutica Sinica ; (12): 226-2016.
Article em Zh | WPRIM | ID: wpr-779159
Biblioteca responsável: WPRO
ABSTRACT
Cyclin-dependent kinase-5 (Cdk5) is a kind of Ser/Thr kinases in the signaling pathway, which regulates the neural development. The recent studies have confirmed that hyperactivation of Cdk5 is closely associated with the evolution, progression and apoptosis of tumors. The Cdk5 inhibitors have been extensively studied in the drug discovery against cancer. The structure features of these inhibitors and molecular mechanisms of their activities have provided clues for the drug development. In the second generation Cdk5 inhibitors, the ATP-binding pocket, a highly conserved site, has been targeted in the drug design in most cases. In addition, a growing number of peptides has been generated by targeting the protein/protein interfaces of Cdk5.
Palavras-chave
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Acta Pharmaceutica Sinica Ano de publicação: 2016 Tipo de documento: Article
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Acta Pharmaceutica Sinica Ano de publicação: 2016 Tipo de documento: Article